ECO Animal Health Group plc (LON:EAH - Get Free Report) shares passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 73.90 ($1.00) and traded as high as GBX 81.35 ($1.10). ECO Animal Health Group shares last traded at GBX 81 ($1.09), with a volume of 72,018 shares traded.
Analyst Ratings Changes
Separately, Shore Capital reiterated a "buy" rating and issued a GBX 150 price objective on shares of ECO Animal Health Group in a research report on Monday, July 14th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of GBX 150.
View Our Latest Research Report on EAH
ECO Animal Health Group Price Performance
The company has a market capitalization of £58.86 million, a price-to-earnings ratio of 3,588.93 and a beta of -0.05. The company has a current ratio of 2.96, a quick ratio of 2.14 and a debt-to-equity ratio of 4.81. The company has a 50 day moving average price of GBX 74.98 and a 200 day moving average price of GBX 64.76.
ECO Animal Health Group (LON:EAH - Get Free Report) last announced its quarterly earnings data on Monday, July 14th. The company reported GBX 2.49 EPS for the quarter. ECO Animal Health Group had a return on equity of 1.27% and a net margin of 1.17%.
Insider Transactions at ECO Animal Health Group
In other ECO Animal Health Group news, insider David Hallas bought 29,897 shares of the stock in a transaction on Tuesday, July 15th. The stock was purchased at an average price of GBX 67 per share, with a total value of £20,030.99. Insiders own 11.03% of the company's stock.
About ECO Animal Health Group
(
Get Free Report)
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Recommended Stories
Before you consider ECO Animal Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ECO Animal Health Group wasn't on the list.
While ECO Animal Health Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
